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Abstract
Background: To date, the study of the risks and benefits of breast cancer screening has not included the onset of
persistent pain after breast cancer treatment within the context of population-based screening programs. Our
purpose was to investigate the prevalence of persistent pain and associated factors in women diagnosed with
breast cancer (screening or interval) in the context of a population-based breast cancer screening program in Spain.
Methods: A total of 1,057 women participating in a population-based breast cancer screening program were
diagnosed with breast cancer between 2000 and 2008. The women were treated surgically and followed-up to
2013. The risk of developing persistent pain was estimated through multivariate logistic regression analysis.
Results: Breast cancer was detected during routine screening in 732 women (69.3 %) and emerged as an interval
cancer between two screening rounds in 325 (30.7 %). Persistent pain was present in 118 women (11.3 %). Women
diagnosed through routine screening reported a higher prevalence of persistent pain (12.9 %) than those with
interval cancers (7.8 %)(P < 0.05). Multivariate logistic regression analysis identified two other variables associated
with persistent pain: having a Charlson index > =2 (Odds Ratio [OR]: 4.5 95 % Confidence Interval [CI]: 2.1-9.5) versus
no comorbidities, and having undergone an axillary lymph node dissection (OR: 2.0 95 % CI: 1.0-4.0) versus sentinel
lymph node biopsy.
Conclusions: The prevalence of persistent pain was relatively low. The detection mode was not related to the
onset of persistent pain. The factors associated with persistent pain were a Charlson index > =2 and the
performance of axillary lymph node dissection. Women treated for breast cancer are at risk for developing
persistent pain regardless of the detection mode, especially those with comorbidities and those who have
undergone axillary lymph node dissection.
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Background
Breast cancer is the most frequent malignancy among
Spanish women, with an estimated 25,215 new cases in
2012 [1]. Screening programs and improved treatments
have reduced mortality from this disease [2]. Early detec-
tion allows more effective treatment, but the treatment
itself is not free of complications in the short term or
sequels in the long term. Women with interval cancer
(cancers detected clinically after a negative screening
round and before the following screening invitation)
may not benefit from early detection because of a delay
in diagnosis and less favourable biological tumor char-
acteristics [3].
To date, complications have not been evaluated by ac-
cording to the detection method. Among complications,
persistent pain, defined by some authors as pain in the
breast area, axilla, shoulder or arm for more than
3 months after breast cancer surgery, has been reported
as one of the most frequent long-term complications [4].
Among patients treated surgically for breast cancer, the
prevalence of persistent pain may range from 10 % to
50 % or more, depending on the characteristics of the
population studied, as well as on the definition of per-
sistent pain [4–16]. Several factors have been associated
with the risk of developing persistent pain: young age
[5–7, 10, 12, 14, 16, 17] adjuvant therapies (chemo-
therapy or radiotherapy) [5, 11], axillary lymph node
dissection (ALND) [5–7, 10, 12], and the presence of
comorbidities [5, 16], among others, but the evidence
remains inconclusive.
Given that a substantial number of women are diag-
nosed with breast cancer and that most are treated
surgically, a large number of women can be expected
to experience persistent pain, which may negatively
affect their quality of life and psychosocial well-being.
Therefore, from the perspective of public health, persist-
ent pain in women treated for breast cancer is an import-
ant health problem. To date, study of the risks and
benefits of breast cancer screening has not included the
onset of complications and sequels after breast cancer
treatment within the context of population-based screen-
ing programs. Women with screen-detected breast cancer
benefit from early detection and have better survival
[18, 19]. However, no studies have evaluated whether
these women also benefit from fewer complications
and have less persistent pain in the long term. The
risk-benefit analysis of breast cancer screening should
include information on complications in women with
screen-detected breast cancer.
We aimed to investigate the prevalence of persistent
pain and associated factors in women diagnosed with
breast cancer (screening or interval) in the context of




Our study population was drawn from the CAMISS co-
hort, which includes 1,086 women with breast cancer from
a population-based screening program. These women were
diagnosed with breast cancer between 2000 and 2008 and
were followed-up to December 2013. Breast cancer was de-
tected in routine screening or emerged as an interval can-
cer. The definition of interval cancer used was that
proposed in the European guidelines as “primary breast
cancer arising after a negative screening episode, with or
without further assessment, and before the next screening
invitation, or within 24 months for women who reached
the upper age limit” [20].
All women were resident in Spain, were aged 50 to
69 years at diagnosis, and were from 2 Spanish regions:
the Canary Islands and Catalonia. In Spain, all women
aged 50 to 69 years are actively invited to participate in
the population-based screening program by a written
letter every 2 years, following the European guidelines
for Quality Assurance in Mammographic Screening
Recommendations. This nationwide program achieves
the required standards [21].
Study variables
Interval cancers were identified by merging data from
the registers of screening programs with population-
based cancer registries, the regional Minimum Data
Set and hospital-based cancer registries. Further details on
the identification of interval cancers are reported else-
where [3]. For the purpose of this study, only two
categories were considered in the final analysis: interval or
screening cancers.
Women’s age at diagnosis was obtained from the date
of birth and date of the screening mammogram. The
presence of other comorbidities was identified at clinical
records review. All the comorbidities recorded in the
clinical records at the date of breast cancer diagnosis
were considered, although we only included the comor-
bidities needed to calculate the Charlson index [22].
Tumor-related characteristics (histological type and grade,
focality, size, lymph node involvement, estrogen receptor
[ER], progesterone receptor [PR], human epidermal
growth factor receptor 2 [HER2] status) were obtained
from the cancer registries, hospital-based registers, and
from clinical records. Based on expression of ER, PR
and HER2, tumors were classified into four phenotypes: 1)
luminal A: ER+/HER2- OR PR+/HER2-; 2) luminal B:
ER+/HER2+ or PR+/HER2+; 3) HER2: ER-/PR-/HER2+;
and 4) triple-negative: ER-,PR-, HER2- [23].
Information on the treatments received was obtained
from the clinical records. Two types of surgery were
considered: radical or conservative. Women with radical
surgery included all those who underwent mastectomies,
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whether radical or simple. In both cases, the breast is
completely removed. In conservative surgery, only the
tumor and some of the healthy surrounding tissue are
excised, and the breast is fully preserved.
In addition to breast surgery, some women could
undergo an ALND, also a surgical procedure that incises
the axilla to identify, examine and remove lymph nodes.
Sentinel lymph node biopsy (SLNB) has been proposed
as an alternative to ALND, because it produces less mor-
bidity [24]. SLNB was a relatively new technique during
the study period and was introduced at different times
in each hospital. It was introduced in the first hospital in
2000 and in the last hospital in 2004.
Chemotherapy, radiotherapy, hormone therapy or spe-
cific Her2 treatment may have been used as an adjuvant
therapy before and/or after surgery.
Outcome variables
The onset of breast cancer treatment complications
was reviewed throughout the patient’s clinical course,
starting from the date of surgery until the end of follow
up. The reviewers recorded the onset of the following
complications: persistent pain, lymphedema, anxiety, fa-
tigue, disability, osteoporosis, agranulocytosis, lymphope-
nia, seroma, weight gain, paraesthesia, infection, necrosis,
cardiomyopathy, cognitive dysfunction, pneumonitis,
mycosis, hypothyroidism, renal toxicity, ototoxicity, pul-
monary fibrosis and other complications not specified.
The definition of persistent pain was the following: a
woman was considered to have persistent pain if she felt
pain in the area of the operated breast, axilla, shoulder
or arm in some of the follow-up visits at least 3 months
after surgery [25]. The pain could be neuropathic or not.
According to this definition, in the clinical record re-
view, a woman was considered to have pain if, in some
of the follow-up visits (at least one visit 3 months after
surgery), the physician assessing her reported the presence
of pain in some of the previously described areas
(operated breast area, axilla, shoulder or arm). The
clinical record review was performed by trained staff
(nurses) at each of the participating centers.
Statistical analysis
We performed a descriptive analysis of the study variables.
The prevalence of overall complications were estimated,
as well as the prevalence of persistent pain and its 95 %
confidence intervals (CI). The prevalence of overall com-
plications was computed as the number of women with at
least one complication among the total number of women
with information on the complications variable.
Comparisons were made between women with
screening-detected cancers and those with interval cancers.
Statistical significance was estimated using the chi-square
or Fisher exact tests, since all the study variables were
considered as categorical. The prevalence of persistent
pain were described by detection mode, age at diagnosis,
Charlson index, tumor characteristics and breast cancer
treatments. The crude and adjusted risk of developing
persistent pain was estimated through a multivariate logis-
tic regression analysis. The multivariate logistic regression
model included the following variables: detection method,
age, Charlson index, histological type, phenotype, axillary
treatment, neoadjuvant treatment and chemotherapy after
surgery. Statistical significance was considered if the
P-value was <0.05. Statistical analyses were performed
using the SPSS statistical package (version 12.0).
Results
Of the 1,086 women included in the CAMISS cohort,
most were treated surgically (n = 1,057, 97.3 %) and were
included in the analysis. Breast cancer was detected dur-
ing routine screening mammograms in 732 women
(69.3 %) and emerged as interval cancer in 325 (30.7 %).
The characteristics of the women and detected tumors
by detection mode, as well as the treatments provided,
are shown in Table 1. Women with interval cancers had
larger tumors, with a higher percentage of positive
lymph node involvement (44.4 % vs. 25.8 %; P < 0.001).
The percentage of ductal in situ tumors was higher
among women with screen-detected tumors (11.1 % vs.
3.8 %; P < 0.001). Histological grade III was more fre-
quent among women with interval cancers (42.3 % vs.
24.2 %; P < 0.001), as well as among those with triple
negative phenotype (16.1 % vs. 8.1 %; P < 0.001). Women
with interval cancer were younger than those with screen-
detected cancers (P < 0.001). No differences in the Charlson
index were observed according to the detection method.
Most women underwent conservative surgery (n = 829,
78.6 %). According to the detection method, radical surgery
was more common among women with interval cancers
(33.0 %) than in those with screen-detected cancers
(16.3 %) (P < 0.001). ALND was more common in women
with interval cancers than in those with screen-detected tu-
mors (78.4 % vs. 70.6 % P < 0.05). Neoadjuvant therapy was
more frequent in women in the interval cancer group than
in the screening group (24.0 % vs. 4.2 % P < 0.001).
A total of 313 women (29.6 % 95 % CI: 27.4 –33.0) expe-
rienced at least one complication during follow-up. Among
all the complications reported, the most frequent was per-
sistent pain, which was present in 118 women (11.3 %
95 % CI: 9.4 –13.2). Women who were diagnosed in rou-
tine screening reported a higher prevalence of persistent
pain (12.9 % 95 % CI: 10.4 –15.3) than those with tumors
that emerged as interval cancers between two screening
rounds (7.8 % 95 % CI: 4.8 –10.7) (P < 0.05) (Table 1).
Table 2 shows the prevalence of persistent pain
according to women’s characteristics, the detection
method and tumor characteristics. Women aged 65–70
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Table 1 Tumor and women’s characteristics, treatments performed and frequencies of complications, according to detection method
Screen-detected cancers Interval cancers P-value Total
N % N % N %
Total women 732 69.3 325 30.7 1057 100.0
Tumor size (n = 936) <0.001
< = 10 mm 198 31.9 40 12.7 238 25.4
11 to 20 mm 273 44.0 117 37.0 390 41.7
21 to 50 mm 132 21.3 133 42.1 265 28.3
> 50 mm 17 2.7 26 8.2 43 4.6
Lymph node involvement (n = 1054) <0.001
Negative 542 74.2 180 55.6 722 68.5
Positive 188 25.8 144 44.4 332 31.5
Number of positive nodes (n = 870) <0.05
= <3 515 92.5 268 85.6 783 90.0
4–20 38 6.8 41 13.1 79 9.1
> 20 4 0.7 4 1.3 8 0.9
Histological type (n = 1050) <0.001
Ductal Infiltrante 531 72.7 242 75.6 773 73.6
Ductal In situ 81 11.1 12 3.8 93 8.9
Lobular 63 8.6 36 11.3 99 9.4
Otros 55 7.5 30 9.4 85 8.1
Focality (n = 894) 0.643
Unifocal 487 83.5 256 82.3 743 83.1
Multifocal and/or multicentric 96 16.5 55 17.7 151 16.9
Histological grade (n = 914) <0.001
I 181 28.8 48 16.8 229 25.1
II 249 39.6 104 36.4 353 38.6
III 152 24.2 121 42.3 273 29.9
Not applicable 46 7.3 13 4.5 59 6.5
Tumor phenotype (n = 769) <0.001
Luminal A 275 56.9 132 46.2 407 52.9
Luminal B 131 27.1 79 27.6 210 27.3
HER2 38 7.9 29 10.1 67 8.7
Triple negative 39 8.1 46 16.1 85 11.1
Age (n = 1057) <0.001
50–54 193 26.4 117 36.0 310 29.3
55–59 183 25.0 100 30.8 283 26.8
60–64 211 28.8 67 20.6 278 26.3
65–70 145 19.8 41 12.6 186 17.6
Charlson index (n = 1057) 0.380
0 535 73.1 241 74.2 776 73.4
1 129 17.6 53 16.3 182 17.2
> =2 68 9.3 31 9.5 99 9.4
Surgery (n = 1055) <0.001
Radical 119 16.3 107 33.0 226 21.4
Conservative 612 83.7 217 67.0 829 78.6
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years had a lower prevalence of persistent pain (8.7 %)
than those from other age groups (50–54 years: 11.8 %,
55–59 years: 13.2 %, 60–64 years: 10.5 %). However,
these differences were not statistically significant (P =
0.483). A gradient was observed in the prevalence of per-
sistent pain, according to the Charlson index. Women
without other comorbidities (Charlson index = 0) had
the lowest prevalence of persistent pain (8.5 %), whereas
those with a Charlson index > =2 had the highest preva-
lence of persistent pain (21.9 %) (P < 0.001). According
to the detection method, women with screen-detected
tumors had a higher prevalence of persistent pain than
women with interval tumors (12.9 % vs. 7.8 % P < 0.05).
When tumor characteristics were analyzed, the preva-
lence of persistent pain was higher among women with
lobular histological type tumors (14.3 %) (P < 0.05). No
statistically significant differences in the prevalence of
persistent pain were observed by tumor size, lymph node
involvement, focality, histology or phenotype.
Table 3 shows the prevalence of persistent pain ac-
cording to the treatments provided. The prevalence of
persistent pain was higher among women who under-
went ALND than in those who underwent SLNB only
(13.7 % vs. 6.7 % P < 0.001). The prevalence was also
higher in women who received chemotherapy after sur-
gery than those who did not (14.5 % vs. 8.4 % P < 0.01).
No statistically significant differences in persistent
pain prevalence were observed according to the type of
surgery, neoadjuvant therapy, radiotherapy, hormone
therapy or Her2 treatment after surgery.
The factors associated with persistent pain were de-
scribed using univariate and multivariate logistic regres-
sion models (Table 4). In the univariate analysis, five
factors were associated with persistent pain (detection
method, Charlson index, histological type, axillary treat-
ment and chemotherapy after surgery). In the multivari-
ate model, only the Charlson index remained statistically
significant, with the highest odds ratio (OR). Women
with a Charlson index > =2 had an OR of 4.5 (95 % CI:
2.1 –9.5) with respect to women without comorbidities
(Charlson index = 0). Persistent pain was also more fre-
quent among patients with ALND than in those with
SLNB only, although this result was at the limit of statis-
tical significance (OR: 2.0 95 % CI: 1.0 – 4.0).
Discussion
The prevalence of persistent pain was higher in women
diagnosed within the screening program than in those
with interval cancers. Our first hypothesis was that,
given the benefits of screening (early diagnosis, with less
aggressive tumors), the treatment of screen-detected
cancer would be less intensive and, therefore, have
fewer complications. Surprisingly, we observed that
women diagnosed within the screening program did
not benefit from fewer complications; on the contrary,
they initially seemed to have more persistent pain.
However, in the multivariate analysis only two factors
showed a clear association with the onset of persistent
pain: the presence of other comorbidities and the per-
formance of an ALND.
The prevalence of persistent pain in our study was
11.3 %. This prevalence is relatively low compared with
that in other studies, which include all diagnostic
methods and women of different ages, with values ran-
ging from 10 % to 50 % or more [4, 5, 7–12, 14, 16]. In
our study, information on the presence of persistent pain
was extracted through the medical records review.
Women were considered to have persistent pain if they
Table 1 Tumor and women’s characteristics, treatments performed and frequencies of complications, according to detection method
(Continued)
Axillary treatment: SLNB and ALNDc (n = 994) <0.05
Only SLNB 201 29.4 67 21.7 268 27.0
ALND 483 70.6 243 78.4 726 73.0
Neoadjuvant therapy (n = 1057) <0.001
No 701 95.8 247 76.0 948 89.7
Yes 31 4.2 78 24.0 109 10.3
Adjuvant therapy (n = 1051) 0.387
No 16 2.2 10 3.1 26 2.5
Yes 712 97.8 313 96.9 1025 97.5
Any complicationa (n = 1057) 225 30.7 88 27.1 0.229 313 29.6
Persistent painb (n = 1045) 93 12.9 25 7.8 <0.05 118 11.3
aNumber of women with at least one complication
bNumber of women with persistent pain
cSLNB: sentinel lymph node biopsy. In this category only women with SLNB performed were included. ALND: axillary lymph node dissection. This category
includes women with only ALND performed and women with SLNB and ALND
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had pain (either in the arm, breast area or shoulder)
3 months after surgery, but this information had to have
been registered by the physician during the clinical
course. If women had been asked the question “Do you
have any pain?” the prevalence could possibly have been
higher than 11.3 %. Our results might be interpreted as
follows: 11.3 % of women treated for breast cancer had
clinically relevant pain, since pain was recorded in the
medical record. In addition, some cultural differences
may exist in pain perception. In a European survey of
chronic pain, Spanish participants reported the lowest
prevalence of chronic pain (12 %) [26]. Another possible
reason for the low prevalence of persistent pain is that
our patients came from screening and, therefore, had
less aggressive tumors and less use of ALND than
women with breast cancer of all ages, including those
with a symptomatic diagnosis.
Table 2 Prevalence of persistent pain according to detection




Age (n = 1045) 0.483
50–54 (n = 305) 36 (11.8)
55–59 (n = 281) 37 (13.2)
60–64 (n = 275) 29 (10.5)
65–70 (n = 184) 16 (8.7)
Charlson index (n = 1045) <0.001
0 (n = 769) 65 (8.5)
1 (n = 180) 32 (17.8)
> =2 (n = 96) 21 (21.9)
Detection method (n = 1045)
Screen-detected tumors (n = 723) 93 (12.9) <0.05
Interval tumors (n = 322) 25 (7.8)
Tumor characteristics
Tumor size (n = 932) 0.907
< =10 mm (n = 237) 14 (5.9)
11 to 20 mm (n = 387) 28 (7.2)
21 to 50 mm (n = 265) 19 (7.2)
> 50 mm (n = 43) 2 (4.7)
Lymph node involvement (n = 1042) 0.564
Negative (n = 713) 78 (10.9)
Positive (n = 329) 40 (12.2)
Number of positive nodes (n = 866) 0.442
= <3 (n = 781) 54 (6.9)
4–20 (n = 77) 7 (9.1)
> 20 (n = 8) 1 (12.5)
Histological type (n = 1038) <0.05
Ductal (n = 763) 94 (12.3)
In situ (n = 93) 2 (2.2)
Lobular (n = 98) 14 (14.3)
Othter (n = 84) 7 (8.3)
Focality (n = 891) 0.461
Unifocal (n = 741) 56 (7.6)
Multifocal and/or multicentric (n = 150) 14 (9.3)
Histological grade (n = 905) 0.101
I (n = 228) 19 (8.3)
II (n = 348) 46 (13.2)
III (n = 270) 25 (9.3)
Not applicable (n = 59) 3 (5.1)
Tumor phenotype (n = 763) 0.291
Luminal A (n = 404) 41 (10.1)
Luminal B (n = 207) 12 (5.8)
HER2 (n = 67) 5 (7.5)
Triple negative (n = 85) 9 (10.6)
aPercentages were computed as follows: number of women with persistent
pain divided by the total number of women for each category




Surgery (n = 1043)
Radical (n = 224) 27 (12.1) 0.693
Conservative (n = 819) 91 (11.1)
Axillary treatmentb (n = 983) <0.01
Only SLNB (n = 268) 18 (6.7)
ALND (n = 715) 98 (13.7)
Neoadjuvant therapy (n = 1045) 0.090
No (n = 936) 111 (11.9)
Yes (n = 109) 7 (6.4)
Adjuvant therapy post-surgery (n = 1039) 1
No (n = 26) 3 (11.5)
Yes (n = 1013) 115 (11.4)
Chemotherapy (n = 1018) <0.01
No (n = 513) 43 (8.4)
Yes (n = 505) 73 (14.5)
Radiotherapy (n = 998) 0.457
No (n = 155) 15 (9.7)
Yes (n = 843) 99 (11.7)
Hormone therapy (n = 1019) 0.328
No (n = 219) 29 (13.2)
Yes (n = 800) 87 (10.9)
Her2 treatment (n = 1028) 0.790
No (n = 979) 112 (11.4)
Yes (n = 49) 5 (10.2)
aPercentages are computed as follows: number of women with persistent pain
divided by the total number of women for each category
bSLNB: sentinel lymph node biopsy. In this category only women with SLNB
performed were included. ALND: axillary lymph node dissection. This category
includes women with only ALND performed and women with SLNB and ALND
Romero et al. BMC Cancer  (2016) 16:735 Page 6 of 9
Among the risk factors described in the literature,
young age is usually reported to be a risk factor for de-
veloping persistent pain [5–7, 10, 12, 14, 17]. In our
study population, women aged 65–70 years had the low-
est prevalence of persistent pain, but the differences
were not statistically significant. Since our study popula-
tion only comprised women participating in population-
based breast cancer screening programs, we were unable
to investigate persistent pain among women of younger
ages (50 years or younger) or older ages (more than
70 years).
The presence of other comorbidities has been proposed
as an associated factor in the development of persistent
pain [5, 16]. In our study, we investigated the presence of
other comorbidities by using the Charlson index. Women
with a Charlson index equal to 2 or higher had a much
higher risk of developing persistent pain. It is well estab-
lished that previous painful conditions predispose patients
Table 4 Factors associated with persistent pain: univariate and multivariate logistic regression models
Univariate Multivariatea
95 % CI P-value 95 % CI P-value
OR Lower Upper OR Lower Upper
Detection method (n = 1045)
Screening Ref. Ref.
Interval 0.6 0.4 0.9 0.017 0.8 0.4 1.4 0.408
Age (n = 1045)
50–54 Ref. Ref.
55–59 1.1 0.7 1.9 0.618 1.0 0.5 2.0 0.967
60–64 0.9 0.5 1.5 0.632 0.7 0.3 1.6 0.424
65–70 0.7 0.4 1.3 0.282 0.7 0.3 1.7 0.432
Charlson index (n = 1045)
0 Ref. Ref.
1 2.3 1.5 3.7 <0.001 2.8 1.4 5.4 <0.01
> =2 3.0 1.8 5.2 <0.001 4.5 2.1 9.5 <0.001
Histological type (n = 1038)
In situ Ref. Ref.
Ductal 6.4 1.5 26.4 <0.05 0.5 0.1 4.2 0.534
Lobular 7.6 1.7 34.4 <0.01 1.1 0.5 2.7 0.784
Other 4.1 0.8 20.5 0.082 0.6 0.2 2.1 0.422
Phenotype (n = 763)
Luminal A Ref. Ref.
Luminal B 0.5 0.3 1.1 0.074 0.6 0.3 1.3 0.219
Her2 0.7 0.3 1.9 0.495 0.8 0.3 2.3 0.713
Triple negative 1.0 0.5 2.2 0.903 1.1 0.5 2.6 0.800
Axillary treatmentb (n = 983)
Only SLNB Ref. Ref.
ALND 2.2 1.3 3.7 <0.05 2.0 1.0 4.0 <0.05
Neoadjuvant treatment (n = 1045)
No Ref. Ref.
Yes 0.5 0.2 1.1 0.095 0.4 0.1 1.3 0.132
Chemotherapy after surgery (n = 1018)
No Ref. Ref.
Yes 1.8 1.2 2.8 <0.01 1.4 0.7 2.5 0.334
aN = 704 cases were included in the multivariate analysis. The multivariate logistic regression model included the following variables: detection method, age,
Charlson index, histological type, phenotype, axillary treatment, neoadjuvant treatment and chemotherapy after surgery
bSLNB: sentinel lymph node biopsy. In this category only women with SLNB performed were inluded. ALND: axillary lymph node dissection. This category includes
women with only ALND performed and women with SLNB and ALND
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to persistent pain after surgery [5, 7, 16]. In addition,
women with several comorbidities may have more depres-
sion, anxiety and other psychosocial factors that may also
be risk factors for persistent pain [5, 27].
The use of ALND has been described in the literature as
a risk factor for developing persistent pain [6, 7, 10, 12, 14]
and in our study remained a risk factor at the limit of stat-
istical significance in the multivariate analysis. These stud-
ies report that women with an ALND had OR values
between 2.0 and up to 7.7 and, in our study, women with
an ALND had an OR of 2.0. This variability may be partly
due to differences in the reference population: some stud-
ies take women without ALND as the reference, whereas
others take those with SLNB as the reference category.
Some studies have found that chemotherapy is related to
persistent pain [5, 11]. In our study, the univariate analysis
showed that women who received chemotherapy after sur-
gery had a higher risk of persistent pain than those who
did not but this result was not statistically significant in the
multivariate analysis. Therefore, chemotherapy may be as-
sociated with the onset of persistent pain, but other factors
are more strongly associated with to pain.
Our study has some limitations. Pain was not evaluated
with validated instruments such the Visual Analogue
Scale, Numerical Rating Scale or specific pain question-
naires, and could be underestimated. Most published
evidence is based on pain measurement with validated
instruments and therefore our results are not directly
comparable to those of studies using these instruments.
However, the value of reporting pain recorded in the
medical record is a valid measure for clinically relevant
pain, which could be comparable to the prevalence of
moderate/severe pain reported in other studies. More-
over, our study did not collect women’s height and
weight, the two variables used to calculate the body
mass index, a variable that has been proposed as a risk
factor for developing persistent pain [14, 16]. Equally,
variables related to psychosocial factors were not collected,
which are well-established risk factors for persistent pain
[5, 7, 9, 14]. Finally, another limitation of our study is the
lack of information on previous chronic pain conditions
(such as low back pain, osteoarthritis, arthritis or fibro-
myalgia) [5, 16] or breast pain immediately before surgery
[11, 14, 16]; all of these factors have been found to be re-
lated to the onset of persistent pain. Equally, no informa-
tion was gathered on the presence of acute postoperative
pain, another factor that it has been proposed as a risk fac-
tor for persistent pain [7]. However, the absence of these
variables might not change our results on the effect of the
detection method on the development of persistent pain.
This study has some important strengths. It is the first
to evaluate the onset of complications and, specifically,
persistent pain among women diagnosed with breast can-
cer participating in population-based screening programs
in Spain. Our cohort study has a long follow-up period,
with a median of 8.7 (Interquartile Range: 7.2 –10.6)
years.
Conclusions
Our study shows that the detection mode (screening or
interval) has no direct effect on the prevalence of com-
plications and specifically on the onset of persistent pain.
Although women with screen-detected cancer had a
higher prevalence of persistent pain, the multivariate
analysis showed that other factors were also associated
with its onset, namely, Charlson index > =2 and the
performance of an ALND.
In conclusion, the prevalence of persistent pain in our
population of screened women was relatively low, and
women with screen-detected cancers did not benefit from
less persistent pain than women with interval cancer.
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